JP2024512931A5 - - Google Patents
Info
- Publication number
- JP2024512931A5 JP2024512931A5 JP2023556737A JP2023556737A JP2024512931A5 JP 2024512931 A5 JP2024512931 A5 JP 2024512931A5 JP 2023556737 A JP2023556737 A JP 2023556737A JP 2023556737 A JP2023556737 A JP 2023556737A JP 2024512931 A5 JP2024512931 A5 JP 2024512931A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- tautomer
- pharmaceutically acceptable
- acceptable salt
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/081514 | 2021-03-18 | ||
| CN2021081514 | 2021-03-18 | ||
| PCT/CN2022/081544 WO2022194259A1 (en) | 2021-03-18 | 2022-03-17 | Receptor-interacting protein 1 inhibitors, preparations, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024512931A JP2024512931A (ja) | 2024-03-21 |
| JP2024512931A5 true JP2024512931A5 (enExample) | 2025-03-25 |
Family
ID=83321909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023556737A Pending JP2024512931A (ja) | 2021-03-18 | 2022-03-17 | 受容体相互作用タンパク質１阻害剤、その調製、及び使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240217963A1 (enExample) |
| EP (1) | EP4308555A4 (enExample) |
| JP (1) | JP2024512931A (enExample) |
| CN (1) | CN117500795A (enExample) |
| CA (1) | CA3209628A1 (enExample) |
| IL (1) | IL305530A (enExample) |
| WO (1) | WO2022194259A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4709723A1 (en) | 2023-05-10 | 2026-03-18 | Genzyme Corporation | Isoxazolidines as ripk1 inhibitors and use thereof |
| JP2026516095A (ja) | 2023-05-10 | 2026-05-19 | ジェンザイム・コーポレーション | Ｒｉｐｋ１阻害剤としてのイソオキサゾリジン及びその使用 |
| EP4709722A1 (en) | 2023-05-10 | 2026-03-18 | Genzyme Corporation | Isoxazolidines as ripk1 inhibitors and use thereof |
| WO2025185732A1 (zh) * | 2024-03-08 | 2025-09-12 | 山东全重生物医药科技有限公司 | Ripk1抑制剂、其制备方法及其在医药上的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007098352A2 (en) * | 2006-02-16 | 2007-08-30 | Boehringer Ingelheim International Gmbh | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors |
| TW200815426A (en) * | 2006-06-28 | 2008-04-01 | Astrazeneca Ab | New pyridine analogues II 333 |
| US20080076924A1 (en) * | 2006-06-30 | 2008-03-27 | Patrick Betschmann | Piperazines as P2X7 antagonists |
| JP5411867B2 (ja) * | 2007-10-11 | 2014-02-12 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規ｓＥＨ阻害剤およびそれらの使用 |
| EP2240021A4 (en) * | 2008-01-30 | 2011-08-17 | Glaxosmithkline Llc | NEW SEH-HEMMER AND ITS USE |
| US9056865B2 (en) * | 2010-10-20 | 2015-06-16 | Pfizer Inc. | Pyridine-2-derivatives as smoothened receptor modulators |
| EA029056B1 (ru) * | 2012-12-11 | 2018-02-28 | Такеда Фармасьютикал Компани Лимитед | Гетероциклическое соединение |
| EP3224237B1 (en) * | 2014-12-24 | 2024-09-11 | National Institute Of Biological Sciences, Beijing | Necrosis inhibitors |
| WO2016101887A1 (en) * | 2014-12-24 | 2016-06-30 | National Institute Of Biological Sciences, Beijing | Necrosis inhibitors |
| UY36680A (es) * | 2015-05-19 | 2016-12-30 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas como inhibidores de quinasa |
| TW201831464A (zh) * | 2016-11-18 | 2018-09-01 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺 |
| KR102810898B1 (ko) * | 2018-11-20 | 2025-05-23 | 시로낙스 엘티디 | Rip1 억제제 |
| BR112021009610A2 (pt) * | 2018-11-20 | 2021-08-10 | Sironax Ltd | composto, composição farmacêutica, uso de um composto ou composição, e, método de inibir necrose, ferroptose, rip1 humana ou indicações relacionadas |
| KR20200087922A (ko) * | 2019-01-11 | 2020-07-22 | 보로노이바이오 주식회사 | (3-페닐이속사졸리딘-2-일)(피페리딘-4-일)메타논 유도체 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물 |
-
2022
- 2022-03-17 CA CA3209628A patent/CA3209628A1/en active Pending
- 2022-03-17 CN CN202280022439.7A patent/CN117500795A/zh active Pending
- 2022-03-17 US US18/549,923 patent/US20240217963A1/en active Pending
- 2022-03-17 IL IL305530A patent/IL305530A/en unknown
- 2022-03-17 JP JP2023556737A patent/JP2024512931A/ja active Pending
- 2022-03-17 WO PCT/CN2022/081544 patent/WO2022194259A1/en not_active Ceased
- 2022-03-17 EP EP22770611.6A patent/EP4308555A4/en active Pending